Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Bladder cancer drug combo under watch for nerve side effects

NCT ID NCT06657157

First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 18 times

Summary

This study follows about 80 people with advanced bladder cancer who are getting a new two-drug treatment (enfortumab vedotin and pembrolizumab). The goal is to see how often nerve damage (peripheral neuropathy) occurs and how it affects their daily life. Researchers will track symptoms and treatment changes over one year. This is an observational study, meaning no new drugs are tested—just careful monitoring of real-world side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UROTHELIAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Department of Urology, Klinikum rechts der Isar, Technical University Munich

    RECRUITING

    Munich, Bavaria, 81675, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Department of Urology, LMU University Hospital, Ludwig-Maximilians-University Munich

    RECRUITING

    Munich, Bavaria, 81377, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Department of Urology, University Hospital of Würzburg

    RECRUITING

    Würzburg, Bavaria, 97080, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Department of Urology, University Hosptial Augsburg

    RECRUITING

    Augsburg, Bavaria, 86156, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.